{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:22:58Z","timestamp":1791559378031,"version":"4.3.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,17]]},"DOI":"10.7759\/cureus.114638","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:34:23Z","timestamp":1786955663000},"source":"Crossref","is-referenced-by-count":1,"title":["Unexpected Durable Treatment-Free Disease Control After Acalabrutinib Cessation: A Case Report"],"prefix":"10.7759","author":[{"given":"Srikaven","family":"Sriskandarajah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram  K","family":"Muralidhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27546","article-title":"Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy","volume":"100","author":"Hallek M","year":"2025","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy. Am J Hematol. 2025, 100:450-80. 10.1002\/ajh.27546","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.7020","article-title":"Clinical risks for chronic lymphocytic leukemia","volume":"22","author":"Brown JR","year":"2024","unstructured":"Brown JR. Clinical risks for chronic lymphocytic leukemia. J Natl Compr Canc Netw. 2024, 22:10.6004\/jnccn.2024.7020","journal-title":"J Natl Compr Canc Netw"},{"key":"ref3","article-title":"Chronic lymphocytic leukemia","author":"Mukkamalla SK","year":"2026","unstructured":"Mukkamalla SK, Taneja A, Malipeddi D, Master SR. Chronic lymphocytic leukemia . StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2026."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek M","year":"2019","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019, 94:1266-87. 10.1002\/ajh.25595","journal-title":"Am J Hematol"},{"key":"ref5","unstructured":"Acalabrutinib for treating chronic lymphocytic leukaemia. (2021). Accessed. August 10, 2026: https:\/\/www.nice.org.uk\/guidance\/ta689."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.187583","article-title":"TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics","volume":"103","author":"Campo E","year":"2018","unstructured":"Campo E, Cymbalista F, Ghia P, et al.. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica. 2018, 103:1956-68. 10.3324\/haematol.2018.187583","journal-title":"Haematologica"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1512710","article-title":"Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib","volume":"60","author":"Barrientos JC","year":"2019","unstructured":"Barrientos JC, Burger JA, Byrd JC, et al.. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leuk Lymphoma. 2019, 60:1000-5. 10.1080\/10428194.2018.1512710","journal-title":"Leuk Lymphoma"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman JP","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, et al.. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020, 395:1278-91. 10.1016\/S0140-6736(20)30262-2","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17984","article-title":"Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a\u2009pooled analysis from four clinical trials","volume":"196","author":"Allan JN","year":"2022","unstructured":"Allan JN, Shanafelt T, Wiestner A, et al.. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a\u2009pooled analysis from four clinical trials. Br J Haematol. 2022, 196:947-53. 10.1111\/bjh.17984","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4450824","article-title":"Ibrutinib plus obinutuzumab as frontline therapy for chronic lymphocytic leukemia is associated with a lower rate of infusion-related reactions and with sustained remissions after ibrutinib discontinuation: a single-arm, open-label, phase 1b\/2 clinical trial NCT0231576","volume":"2022","author":"Castro JE","year":"2022","unstructured":"Castro JE, Lengerke-Diaz PA, Velez Lujan J, et al.. Ibrutinib plus obinutuzumab as frontline therapy for chronic lymphocytic leukemia is associated with a lower rate of infusion-related reactions and with sustained remissions after ibrutinib discontinuation: a single-arm, open-label, phase 1b\/2 clinical trial NCT0231576. Adv Hematol. 2022, 2022:4450824. 10.1155\/2022\/4450824","journal-title":"Adv Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/522043-unexpected-durable-treatment-free-disease-control-after-acalabrutinib-cessation-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:34:34Z","timestamp":1786955674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/522043-unexpected-durable-treatment-free-disease-control-after-acalabrutinib-cessation-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.114638","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}